C4 Therapeutics, Inc. Overview
Pro stress-test →C4 Therapeutics is a clinical-stage biopharmaceutical company that develops novel therapeutic candidates to degrade disease-causing proteins. The company is focused on delivering targeted protein degradation science to create a new generation of medicines that transform patients' lives.
Strategic Profile
Pro stress-test →The lead product candidate is Cemsidomide, an orally bioavailable MonoDAC degrader of protein in Phase 1/2 clinical trials targeting IKZF1 and IKZF3 for multiple myeloma and non-Hodgkin lymphomas. The company has strategic collaborations with F. Hoffmann-La Roche Ltd, Biogen MA, Inc., and Merck entities.
Competitive Landscape
Pro stress-test →Competitors include Nurix Therapeutics, Kymera Therapeutics, Shattuck Labs, Arvinas, Cullinan Therapeutics, and other targeted protein degradation focused companies. C4 Therapeutics differentiates through its Degronimid platform and collaborations with major pharma partners.
Industry Context
C4 Therapeutics, Inc. operates in Biopharmaceuticals - Targeted Protein Degradation.
Key facts
Founded: 2015 · Headquarters: Watertown, Massachusetts · Revenue: $35.58M (2024) · Market cap: $268M